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Although b-cryptoxanthin, a xanthophyll carotenoid, has been shown to exert an anabolic effect on bone
calciﬁcation, little attention has been paid thus far to the precise mechanism of bone remodeling. Daily
oral administration of b-cryptoxanthin signiﬁcantly inhibited osteoclastic activation as well as reduction
of bone volume in ovariectomized mice. In vitro studies revealed that b-cryptoxanthin inhibited differ-
entiation and maturation of osteoclasts by repression of the nuclear factor-kB-dependent transcriptional
pathway. Our results suggest that supplementation with b-cryptoxanthin would be beneﬁcial for pro-
phylaxis and for therapy of metabolic bone diseases associated with abnormal osteoclast activation.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Bone homeostasis is complexly regulated by bone-resorbing
osteoclasts and bone-forming osteoblasts (1). Osteoclasts are
multinucleated cells derived from hematopoietic stem cells,
whereas the osteoblast lineage is derived from primitive multi-
potent mesenchymal stem cells. Imbalance between regulation by
osteoclasts and by osteoblasts results in certain metabolic bone
diseases including osteoporosis (2).
b-Cryptoxanthin, a major carotenoid routinely found in human
serum, is primarily obtained from citrus fruits (3). Several inde-
pendent lines of evidence suggest a relationship between b-cryp-
toxanthin and pathophysiology (4). b-cryptoxanthin alleviated
diet-induces nonalcoholic steatohepatitis by suppressing inﬂam-
matory gene expression (5). In addition, a high serum b-cryptox-
anthin level is associated with a lower risk of lung cancer death (6).
Moreover, serum b-cryptoxanthin is inversely associated with the
risk of human osteoporosis (7), and b-cryptoxanthin shows an
anabolic effect on bone calciﬁcation in both in vitro and in vivo
studies (8,9). Although several studies have been performed, thea, Ishikawa 920-1192, Japan.
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rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).mechanisms of bone remodeling by b-cryptoxanthin remain un-
clear at the cellular and molecular levels. In the present study, we
attempt to show a role and mechanisms of b-cryptoxanthin in the
pathogenesis of bone diseases.
The protocol employed here meets the guidelines of the Japa-
nese Society for Pharmacology andwas approved by the Committee
for Ethical Use of Experimental Animals at Kanazawa University.
Eight-week-old female ddY mice were subjected to ovariectomy
(OVX) or sham operation in aseptic environments, as described
previously (10). Ovariectomized mice received daily oral supple-
mentation of b-cryptoxanthin freshly dissolved in drinking water at
concentrations of 1 mg/L or 10mg/L. Nonesteriﬁed b-cryptoxanthin
for experiments was prepared and processed as described, and the
purity of the b-cryptoxanthin obtained was 96% according to HPLC
analysis (5). No signiﬁcant change was observed in the amount of
daily intake of drinking water by mice, irrespective of the con-
centrations of b-cryptoxanthin used (data not shown). Mice were
killed by decapitation 28 days after operation, followed by dissec-
tion of vertebrae and subsequent ﬁxation with 10% formalin. Bone
histomorphometric analyses were performed on vertebrae, as
previously described (11). In brief, the bone volume-to-tissue vol-
ume (BV/TV) ratio was measured by Von Kossa staining. Bone for-
mation rate (BFR) was analyzed by calcein double-labeling. Mice
were injected twice with calcein at a 3-day interval and were killedr B.V. on behalf of Japanese Pharmacological Society. This is an open access article
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were analyzed by staining with toluidine blue and with tartrate-
resistant acid phosphatase (TRAP), respectively. Analyses were
performed with the Osteomeasure Analysis System (Osteometrics,
Atlanta, GA), according to standard protocols.
Preosteoclastic RAW264.7 cells were cultured with 20 ng/ml re-
ceptor activator of nuclear factor-kB (NF-kB) ligand (RANKL) (R&D
systems, Minneapolis, MN, USA) for 4 consecutive days. TRAP
staining, actin ring assay, pit formation assay, and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
assay were performed, as previously described (12). For the lucif-
erase assay, cells were transfectedwith luciferase reporter vectors by
the Lipofection method using Lipofectamine LTX/Plus reagent
(Invitrogen, Carlsbad, CA, USA) followed by the preparation of cell
lysates and determination of luciferase activity using speciﬁc sub-
strates in a luminometer (ATTO Corp., Tokyo, Japan). Transfection
efﬁciency was normalized to the activity of Renilla luc. Pre-
osteoblastic MC3T3-E1 cells were cultured in the presence of dif-
ferentiation cocktails (50 mg/ml ascorbic acid and 5 mm b-glycer-
ophosphate). Determination of alkaline phosphatase (ALP) activity
and Ca2þ accumulationwas done as indices of cellular differentiation
and maturation, respectively.
All results are expressed as mean ± standard error. Statistical
signiﬁcance was determined by two-tailed unpaired Student's t test
or one-way analysis of variance with Bonferroni/Dunnett post hoc
test.
We ﬁrst administered b-cryptoxanthin orally in drinking water
to ovariectomizedmice for 28 consecutive days at concentrations of
1 mg/L and 10 mg/L. b-Cryptoxanthin administration did not affect
body weight of mice, irrespective of OVX (Fig. 1A). Although OVX
markedly decreased uterine weight determined 28 days after
operation, b-cryptoxanthin did not signiﬁcantly affect the OVX-
induced loss of uterine weight at the concentrations used
(Fig. 1B). Under these experimental conditions, a marked reduction
was observed in cancellous bone stained by Von Kossa staining in
vertebrae of ovariectomized mice compared with that in sham-
operated mice (Fig. 1C). However, in vertebrae of ovariectomized
mice administered b-cryptoxanthin at 10 mg/L, a marked inhibition
of loss of cancellous bone was observed (Fig. 1C). Quantiﬁcation of
these data clearly revealed that supplementation with 10 mg/L b-
cryptoxanthin signiﬁcantly suppressed the reduction of BV/TV ratio
in cancellous bone of ovariectomized mice without affecting that in
sham-operated mice (Fig. 1D).
To deﬁne the cellular basis of the preventive effect of b-cryp-
toxanthin on bone loss, histomorphometric analyses of vertebrae
were performed. In vertebrae of ovariectomized mice, signiﬁcant
increases were observed in the osteoclastic indices, extent of
osteoclast surface/bone surface (Oc.S/BS; Fig. 2A and B), and
number of osteoclast/bone perimeter (N.Oc/B.Pm; Fig. 2A and C)
and in the osteoblastic index, number of osteoblast/bone perim-
eter (N.Ob/B.Pm; Fig. 2D). The administration of b-cryptoxanthin
at 10 mg/L resulted in signiﬁcant inhibition of the increases of
Oc.S/BS and N.Oc/B.Pm to the level observed in sham-operated
mice (Fig. 2AeC) but not of elevated N.Ob/B.Pm (Fig. 2D). In
addition, the administration of b-cryptoxanthin did not affect BFR,
irrespective of OVX (Fig. 2E). Moreover, b-cryptoxanthin at 10 mg/
L did not affect BFR of 8-week-old female mice (Fig. 2F). According
to the BV/TV ratios, b-cryptoxanthin could affect bone volume by
prevention of osteoclastic activation rather than that of osteo-
blastic function.
We next investigated the possible effect of b-cryptoxanthin on
cellular differentiation and maturation of bone-resorbing osteo-
clasts. For this purpose, preosteoclastic RAW264.7 cells were
cultured with RANKL in either the presence or absence of b-cryp-
toxanthin at concentrations of 1e20 mM for 4 consecutive days,followed by TRAP staining for counting TRAP-positive multinu-
cleate cells (MNCs). b-Cryptoxanthin was effective in signiﬁcantly
decreasing the number of TRAP-positive MNCs in a concentration-
dependent manner (Fig. 3A and B), but it failed to affect MTT
reduction as an index of cellular survival at the concentrations
tested (Fig. 3C). Sustained exposure to b-Cryptoxanthin led to the
marked decrease in mRNA expression of osteoclastic marker genes,
Cathepsin K (Ctsk) and Trap, in RAW264.7 cells (Fig. 3D). Further-
more, b-cryptoxanthin signiﬁcantly decreased the number of actin
rings (Fig. 3E and F) and area of pit formation (Fig. 3E and G) in
RANKL-treated RAW264.7 cells. These results indicate that b-
cryptoxanthin prevents the differentiation and maturation of
osteoclasts.
Next, we attempted to elucidate the mechanism underlying
the inhibition by b-cryptoxanthin of osteoclastic function. Thus,
transcriptional activities of NF-kB, activator protein-1 (AP-1), and
the nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1)
(13), all of which are known master transcription factors of
osteoclastogenesis, were monitored in RAW264.7 cells. b-Cryp-
toxanthin signiﬁcantly repressed the activity of NF-kB-luc but not
that of AP-1-luc or NFATc1-luc (Fig. 3H) despite no marked
alteration of mRNA expression in p65, c-Fos, c-Jun and Nfatc1
(Fig. 3I).
The importance of the present results is that daily oral sup-
plementation of xanthophyll carotenoid b-cryptoxanthin signiﬁ-
cantly and selectively prevented osteoclastic activation in
ovariectomized mice without affecting osteoblastic function,
resulting in the inhibition of bone loss in vivo. Moreover, b-cryp-
toxanthin markedly inhibited RANKL-induced osteoclastic differ-
entiation and maturation in association with the inhibition of
transcriptional activity of the transcription factor NF-kB. Although
previous studies were indicative of the modulating effects of b-
cryptoxanthin on bone formation and bone remodeling in vivo
(9,14), this is the ﬁrst demonstration that b-cryptoxanthin pre-
vents bone loss induced by ovariectomy by preferential distur-
bance of osteoclastic activation rather than by modulation of
osteoblastic function.
In this study, we employed 8-week-old ddY female mice for the
OVX operation to replicate the in vivo experimental conditions
often used previously (15). Given that mice are considered to be
still undergoing skeletal development at this age, this develop-
ment could be one reason why b-cryptoxanthin did not signiﬁ-
cantly prevent the increase in osteoblast numbers with signiﬁcant
amelioration of the increased histomorphometric osteoclast pa-
rameters in ovariectomized mice. Indeed, as shown in Fig. 2F, b-
cryptoxanthin did not affect BFR of 8-week-old female mice.
Moreover, in our preliminary experiments, b-cryptoxanthin, at
concentrations affecting osteoclastogenesis (1e20 mM), did not
affect alkaline phosphatase activity or calcium accumulation in
osteoblasts in vitro (Supplemental Fig. 1A and B), suggesting that
osteoblastogenesis cannot be directly regulated by b-cryptox-
anthin in vitro and in vivo. The reason of paradoxical results with
previous reports in terms of the anabolic function of b-cryptox-
anthin could be at least in part accounted for by taking into
consideration of the usage of different animals and cells, devel-
opmental stages of animals, or the purity and concentration of b-
cryptoxanthin. At any rate, we speculate that b-cryptoxanthin
ameliorates the increased osteoclastic parameters through a
mechanism relevant to predominant interference with the
RANKL/NF-kB signaling pathway in osteoclasts, without affecting
the increased osteoblastic indices, after estrogen deﬁciency in
ovariectomized mice.
The reasonwhy b-cryptoxanthin failed to signiﬁcantly affect the
bone mass in sham-operated mice in vivo but inhibited in vitro
osteoclastogenesis is unclear. It may be that the in vitro analysis was
Fig. 1. Oral supplementation of b-cryptoxanthin inhibits OVX-induced bone loss. Eight-week-old female ddY mice were subjected to OVX, followed by daily oral supple-
mentation of b-cryptoxanthin at 1 mg/L and 10 mg/L for 28 consecutive days (sham-control, n ¼ 13; sham-b-cryptoxanthin 1 mg/L, n ¼ 12; sham-b-cryptoxanthin 10 mg/L, n ¼ 11;
OVX-control, n ¼ 12; OVX-b-cryptoxanthin 1 mg/L, n ¼ 12; OVX-b-cryptoxanthin 10 mg/L, n ¼ 12). (A) Body weight and (B) uterine weight. Typical pictures of Von Kossa staining are
shown in the panel (C), while quantitative BV/TV data are shown in the panel (D). **P < 0.01, signiﬁcantly different from each control value obtained in sham-operated mice.
#P < 0.05, signiﬁcantly different from the value obtained in OVX-control mice.
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cultured with RANKL alone, in contrast to the in vivo situation in
which other cells besides osteoclasts are present and a variety of
cytokines other than RANKL are expressed in the bone. Onepossibility is that b-cryptoxanthin inhibits osteoclastic differentia-
tion and maturation by preferential interference with signaling
processes mediated by RANKL in osteoclasts. The present ﬁnding
that b-cryptoxanthin signiﬁcantly inhibited NF-kB-luc activity only
Fig. 2. Oral supplementation of b-cryptoxanthin inhibits OVX-induced osteoclastic activation. Eight-week-old female ddY mice were subjected to OVX, followed by oral sup-
plementation of b-cryptoxanthin, and subsequent determination of different parameters for bone formation and resorption on 28 days after operation (sham-control, n ¼ 8; sham-b-
cryptoxanthin 1 mg/L, n ¼ 6; sham-b-cryptoxanthin 10 mg/L, n ¼ 8; OVX-control, n ¼ 8; OVX-b-cryptoxanthin 1 mg/L, n ¼ 8; OVX-b-cryptoxanthin 10 mg/L, n ¼ 8). Typical pictures of
TRAP staining are shown in the panel (A), while different quantitative analyses were done with determinations of (B) Oc.S/BS, (C) N.Oc/B.Pm, (D) N.Ob/B.Pm, and (E) BFR, respectively.
*P < 0.05, **P < 0.01, signiﬁcantly different from each control value obtained in sham-operated mice. #P < 0.05, signiﬁcantly different from the value obtained in OVX-control mice. (F)
Eight-week-old female ddY mice were administrated b-cryptoxanthin and calcein, and subsequent determination of BFR (control, n ¼ 3; b-cryptoxanthin 10 mg/L, n ¼ 3).
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Fig. 3. b-cryptoxanthin inhibits osteoclastic differentiation and maturation without affecting cell survival. Pre-osteoclastic RAW264.7 cells were cultured with RANKL in
either the presence or absence of b-cryptoxanthin at a concentration range from 1 mM to 20 mM, followed by determination of (A, B) the number of TRAP-positive MNCs, (C) MTT
reduction and (D) genes expression. Quantitative data are shown in the panel (B), while typical pictures are shown in the panel (A). RAW264.7 cells were cultured with RANKL in
either the presence or absence of b-cryptoxanthin, followed by (E, F) actin ring formation assay and (E, G) pit formation assay. Quantitative data are shown in the panel (F, G), while
typical pictures are shown in the panel (E). (H) RAW264.7 cells were transiently transfected with the reporter plasmids, followed by culture in either the presence or absence of b-
cryptoxanthin at 20 mM and subsequent further culture with RANKL for 24 h (I) RAW264.7 cells were cultured with RANKL in either the presence or absence of b-cryptoxanthin at
20 mM for 24 h, followed by determination of genes expression. *P < 0.05, **P < 0.01, signiﬁcantly different from each control value obtained in the absence of b-cryptoxanthin.
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support to this idea.
Long-term intake of b-cryptoxanthin-rich foods gradually in-
creases blood b-cryptoxanthin levels in humans and animals (4).
On the basis of the present ﬁndings, we accordingly propose that
appropriate consumption of b-cryptoxanthin-rich foods such as
Satsumamandarin (Citrus unshiuMarc.) would be beneﬁcial for the
maintenance of bone health and prophylaxis of menopausal oste-
oporosis, by a mechanism relevant to the inhibition of bone-
resorbing osteoclast activation.
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